Long-term effect of @entity7855 on XXXX after radical prostatectomy: 3-year follow-up.

@entity1 @entity1671 @entity323 @entity227 @entity7855 @entity10
OBJECTIVES: To evaluate the long-term effect and safety of @entity7855 for the treatment of @entity323 after radical prostatectomy (RP). METHODS: The study consisted of 91 @entity1 with @entity323 from our institution who received oral @entity7855 after RP. We surveyed these @entity1 using a self-administered questionnaire during the first year of @entity7855 use to determine treatment satisfaction, @entity1 compliance, and safety. Those who had responded positively to the drug were surveyed again 3 years later (n = 48). @entity7855 was prescribed at a dose of 50 mg and increased to 100 mg if needed. Data were collected from a self-administered questionnaire using the abridged five-item version of the International Index of Erectile Function questionnaire, referred to as the Sexual Health Inventory of @entity1 , and the @entity323 Inventory of Treatment Satisfaction. The @entity1 were stratified according to the type of nerve-sparing (NS) RP procedure they underwent: bilateral NS, unilateral NS, and non-NS. RESULTS: At 3 years, 31 (71%) of the 43 @entity1 who had returned the second surveys were still responding to @entity7855 . Of these 31 respondents, 10 (31%) had augmented their dose from 50 to 100 mg. The dropout rate was 27%; 6 of 12 had discontinued because of the return of natural erections, 5 because of a loss of efficacy, and 1 because his spouse had died. No differences were found in the 1-year and 3-year five-item International Index of Erectile Function (Sexual Health Inventory of @entity1 ) and @entity323 Inventory of Treatment Satisfaction scores between the NS groups. The most common side effects at 3 years were @entity10 (12%), @entity1671 (10%), and @entity227 (2%). No @entity1 discontinued the drug at 3 years because of side effects. CONCLUSIONS: The results of this study indicate that the vast majority of @entity1 with @entity323 after RP who initially respond to @entity7855 continue to do so at 3 years and are satisfied and compliant with the treatment regimen.
